Pharmaceutical Business Review

NOVEMBER 27, 2024

The label extension application is supported by positive Phase III data from adolescent trials reported in May this year. In the US and Canada, the application also includes two-year antibody persistence data, demonstrating that 97% of subjects maintained their immune response after 24 months.

Vaccines 52

Vaccines Labelling Immunity Immunization 52

The Thyroid Pharmacist

NOVEMBER 29, 2023

This is because I had learned about various adulterants found in supplements, how some supplement manufacturers don’t actually put the products that are on the label in the bottle, or that the dosages listed on the label may be completely different from what’s in the products. We have 95 expiring in March 2024.)

Health and Personal Care Stores 73

Health and Personal Care Stores Immunization Immunity Labelling 73

European Pharmaceutical Review

MARCH 14, 2024

To mark World Kidney Day 2024, Dr Marshall Fordyce, CEO of Vera Therapeutics, spoke with EPR about the challenges of treating kidney diseases, specifically IgAN, a condition caused by dysfunctional B cells. IgAN is the most common primary glomerulonephritis worldwide. Internet] Vera Therapeutics. cited 2024Mar].

Diabetes 98

Diabetes Labelling Immunization Immunity 98

European Pharmaceutical Review

MARCH 14, 2024

To mark World Kidney Day 2024, Dr Marshall Fordyce, CEO of Vera Therapeutics, spoke with EPR about the challenges of treating kidney diseases, specifically IgAN, a condition caused by dysfunctional B cells. IgAN is the most common primary glomerulonephritis worldwide. Internet] Vera Therapeutics. cited 2024Mar].

Diabetes 98

Diabetes Labelling Immunization Immunity 98

Express Pharma

DECEMBER 9, 2024

Initial results from 20 patients treated as of October 1, 2024, demonstrated an overall response rate (ORR) of 75 per cent (15/20) across all doses tested (0.005 to 1.2mg/kg), with a stringent complete remission (sCR) and complete remission (CR) rate of 20 per cent. No immune cell-associated neurotoxicity syndrome (ICANS) was observed.

Immunization 52

Immunization Immunity Hospitals Labelling 52

PharmaShots

JUNE 1, 2023

We are conducting an open-label, dose-escalation, phase I/II study PDC-LUNG-101 assessing the safety, tolerability, immunogenicity, and the preliminary clinical activity of therapeutic cancer vaccine PDC*lung, associated or not with anti-PD1 treatment in patients with non-small-cell lung cancer (NSCLC). 2015; Zhu et al., 2015; Zhu et al.,

Immunization 40

Immunization Immunity Vaccines Health and Personal Care Stores 40

Pharmaceutical Technology

APRIL 24, 2023

With early nanoparticle studies, researchers often found the human body’s innate immune response to drugs and the short-lasting effects of drugs challenging, as they can also reduce a drug’s efficacy. Since then, the drug has been used off-label in breast cancer and other types of cancer.

Vaccines 59

Vaccines Immunization Immunity Medical Schools 59